ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ZI-JIAN XU M.D.

Cardiovascular Disease

5,895

$342K

484
423 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$58
Average prescription price

Avg: $67

ELIZABETH HEREFORD M.D.

Cardiovascular Disease

5,868

$291K

371
348 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$50
Average prescription price

Avg: $67

RANDALL LOW MD

Cardiovascular Disease

5,860

$325K

365
352 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$55
Average prescription price

Avg: $67

BHOODEV TIWARI MD

Cardiovascular Disease

5,852

$291K

510
440 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$50
Average prescription price

Avg: $67

SANJAY YADLAPALLI M.D.

Cardiovascular Disease

5,850

$400K

536
508 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

JONATHAN HEMPHILL MD

Cardiovascular Disease

5,834

$365K

427
367 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$63
Average prescription price

Avg: $67

KENT WONG MD

Cardiovascular Disease

5,798

$337K

764
678 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$58
Average prescription price

Avg: $67

YOGESH PALIWAL MD

Cardiovascular Disease

5,781

$420K

469
394 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$73
Average prescription price

Avg: $67

CHARLES TSAI M.D.

Cardiovascular Disease

5,775

$388K

598
528 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$67
Average prescription price

Avg: $67

ZOUHEIR ELIAS MD

Cardiovascular Disease

5,765

$545K

603
549 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$95
Average prescription price

Avg: $67

WILLIAM NYITRAY M.D.

Cardiovascular Disease

5,745

$343K

439
391 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

ANTHONY MUSNI MD

Cardiovascular Disease

5,739

$370K

291
272 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$64
Average prescription price

Avg: $67

MOHD. QAISAR KHAN MD

Cardiovascular Disease

5,738

$244K

192
173 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

RAJESH CHAWLA M.D.

Cardiovascular Disease

5,706

$674K

372
335 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$118
Average prescription price

Avg: $67

DAVID MAGORIEN MD

Cardiovascular Disease

5,664

$482K

522
489 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$85
Average prescription price

Avg: $67

RICHARD VALENTE M.D.

Cardiovascular Disease

5,652

$507K

529
452 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$90
Average prescription price

Avg: $67

WILLIAM GIFFORD MD

Cardiovascular Disease

5,641

$312K

332
308 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$55
Average prescription price

Avg: $67

FAYE LEE M.D.

Cardiovascular Disease

5,616

$301K

311
271 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

ROGER ON M.D.

Cardiovascular Disease

5,612

$361K

420
398 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$64
Average prescription price

Avg: $67

FOWROOZ JOOLHAR M.D.

Cardiovascular Disease

5,587

$533K

239
222 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$95
Average prescription price

Avg: $67

DANIEL GOODWIN MD

Cardiovascular Disease

5,585

$494K

470
428 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 28%

$88
Average prescription price

Avg: $67

GARY MILECHMAN M.D.

Cardiovascular Disease

5,531

$467K

622
582 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$84
Average prescription price

Avg: $67

ROBERT CHAMBERS MD

Cardiovascular Disease

5,523

$276K

358
339 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$50
Average prescription price

Avg: $67

PAUL MILLER MD

Cardiovascular Disease

5,514

$191K

297
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

KAUSHAL TAMBOLI M.D.

Cardiovascular Disease

5,511

$459K

642
587 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$83
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank